- Conditions
- Toxic Effect of Organophosphate and Carbamate Insecticides
- Interventions
- Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
- Drug
- Lead sponsor
- Biomedical Advanced Research and Development Authority
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1248
of 1,667
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM)
- Interventions
- Etirinotecan pegol
- Drug
- Lead sponsor
- Lawrence Recht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Ofatumumab (This arm is closed), Ofatumumab + Bendamustine
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- SAR438544, placebo, r-glucagon
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Clostridium Difficile Infection, Diarrhea
- Interventions
- Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant), Clostridium difficile toxoids A and B (high-dose without adjuvant), Placebo: 0.9% normal saline
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 30
- States / cities
- Redding, California • Bristol, Connecticut • Stamford, Connecticut + 25 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Breast Cancer
- Interventions
- Patritumab Deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Newnan, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Cancer
- Interventions
- GSK2118436, GSK1120212
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Hypertension
- Interventions
- LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
- Conditions
- Food Allergy
- Interventions
- Omalizumab, Food Flour Buildup
- Drug
- Lead sponsor
- Kari Christine Nadeau
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
- Conditions
- Acne Vulgaris
- Interventions
- Vehicle, TSN2898
- Drug
- Lead sponsor
- Thesan Pharmaceuticals, Inc.
- Industry
- Eligibility
- 16 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
- Conditions
- Prostate Cancer
- Interventions
- sargramostim, thalidomide, conventional surgery, neoadjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- Up to 120 Years · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
- Interventions
- Dabigatran Etexilate Oral Capsule
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy, Fecal Microbiota Transplantation, Leukapheresis, Placebo Administration
- Biological · Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Asthma
- Interventions
- Daily Text message reminder, Inhaled steroid canister monitor
- Behavioral · Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Interventions
- MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
- Drug · Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pediatric Osteosarcoma
- Interventions
- Cyclophosphamide, Fludarabine, Mesna, Apheresis, SJCARB7H3_41BBL infusion
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Treatment Resistant Depression
- Interventions
- Genotyping assays
- Genetic
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neutropenia, Infection
- Interventions
- Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
- Drug · Biological · Device
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- Not listed
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 13
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Interventions
- BOTOX®
- Biological
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 8
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Aurora, Colorado + 5 more
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
- Interventions
- iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Advanced Colorectal Cancer Expressing HER2
- Interventions
- Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose
- Drug
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
- Interventions
- Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California